KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Evolent Health (EVH) over the last 11 years, with Q3 2025 value amounting to $15.8 million.

  • Evolent Health's Cash from Operations fell 1530.8% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.2 million, marking a year-over-year decrease of 12693.02%. This contributed to the annual value of $18.8 million for FY2024, which is 8683.92% down from last year.
  • According to the latest figures from Q3 2025, Evolent Health's Cash from Operations is $15.8 million, which was down 1530.8% from -$30.3 million recorded in Q2 2025.
  • Evolent Health's Cash from Operations' 5-year high stood at $89.4 million during Q4 2023, with a 5-year trough of -$57.4 million in Q1 2022.
  • In the last 5 years, Evolent Health's Cash from Operations had a median value of $4.9 million in 2024 and averaged $9.4 million.
  • As far as peak fluctuations go, Evolent Health's Cash from Operations soared by 317477.06% in 2024, and later tumbled by 24163.51% in 2025.
  • Quarter analysis of 5 years shows Evolent Health's Cash from Operations stood at $66.7 million in 2021, then tumbled by 46.45% to $35.7 million in 2022, then soared by 150.4% to $89.4 million in 2023, then plummeted by 129.35% to -$26.2 million in 2024, then surged by 160.28% to $15.8 million in 2025.
  • Its Cash from Operations was $15.8 million in Q3 2025, compared to -$30.3 million in Q2 2025 and $4.6 million in Q1 2025.